➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for APD421

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug APD421?

APD421 is an investigational drug.

There have been 10 clinical trials for APD421. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Postoperative Nausea and Vomiting, Vomiting, and Nausea. The leading clinical trial sponsors are Acacia Pharma Ltd and [disabled in preview].

There is one US patent protecting this investigational drug and ten international patents.

Recent Clinical Trials for APD421
Study of APD421 With and Without OndansetronAcacia Pharma LtdPhase 1
Mass-balance Study of [14C]-APD421 in Healthy VolunteersAcacia Pharma LtdPhase 1
Study of APD421 as PONV Treatment (Prior Prophylaxis)Acacia Pharma LtdPhase 3

See all APD421 clinical trials

Clinical Trial Summary for APD421

Top disease conditions for APD421
Top clinical trial sponsors for APD421

See all APD421 clinical trials

US Patents for APD421

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
APD421   Get Started Free METAP2 inhibitors and methods of treating obesity SynDevRx, Inc. (Cambridge, MA)   Get Started Free
APD421   Get Started Free Pyrimidinyl-diazospiro compounds Convergence Pharmaceuticals Limited (Maidenhead, GB)   Get Started Free
APD421   Get Started Free Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Get Started Free
APD421   Get Started Free Drug device configured for wireless communication Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ)   Get Started Free
APD421   Get Started Free 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka-Shi, Osaka, JP)   Get Started Free
APD421   Get Started Free Substituted pyridazines for the treatment of pain INHIBITAXIN LIMITED (Sandwich Kent, GB)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for APD421

Drugname Country Document Number Estimated Expiration Related US Patent
APD421 Argentina AR095828 2033-04-10   Get Started Free
APD421 Australia AU2014250983 2033-04-10   Get Started Free
APD421 Brazil BR112015025892 2033-04-10   Get Started Free
APD421 Canada CA2908993 2033-04-10   Get Started Free
APD421 China CN105431426 2033-04-10   Get Started Free
APD421 Denmark DK2984085 2033-04-10   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.